BioSpace News Archive

Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the fourth quarter and full year ending December 31, 2023.

Cytokinetics, Incorporated announced that the company is scheduled to participate in the following investor conferences in March.

Tandem Diabetes Care, Inc., a global insulin delivery and diabetes technology company, announced that it intends to offer, subject to market conditions and other factors, $250.0 million aggregate principal amount of its Convertible Senior Notes due 2029 in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

BioVie Inc. announced the pricing of its best efforts public offering of 21,000,000 shares of its common stock and warrants to purchase up to 10,500,000 shares of common stock at a combined offering price of $1.00 per share and associated warrant.

Medigene AG announced that the Company has been issued a patent by the Japan Patent Office protecting its inducible Medigene T cell receptor, a control mechanism to regulate efficacy and safety of its T cell receptor engineered T cell therapies.

BioNxt Solutions Inc. is pleased to report that the comparative pharmacokinetic study for its oral dissolvable film based proprietary Cladribine product for the treatment of Multiple Sclerosis has been completed.

The European Society of Gynecological Oncology 2024 Conference has recently made selected abstracts available online.

Akero Therapeutics, Inc. released preliminary topline week 96 results from HARMONY, a Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin in patients with pre-cirrhotic metabolic dysfunction-associated steatohepatitis, fibrosis stage 2 or 3.

Zura Bio Limited a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, announced that members of its senior management team will participate in three conferences in March.

Berlin Cures, a clinical-stage biotechnology company, has reached a significant milestone in its Europe-wide clinical trial for Long COVID, effectively enrolling over 50% of the targeted 114 patients and expanding the study’s inclusion criteria.